Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2003

View Archived Issues

NNC-77-0074 stimulates insulin release and inhibits glucagon secretion

rAHF-PFM reported effective and safe in the management of hemophilia A

New oxytocin antagonists and their use in preterm labor, dysmenorrhea, etc.

Manufacturing approval granted for pitavastatin

Akzo Nobel describes novel ERbeta antagonists in recent patent

Akzo Nobel presents new androgenic agents

Novel PPAR agonists prepared and tested by Indian team

VR-004 shows efficacy in phase IIa erectile dysfunction trial

Piperazine antidiabetic and antiobesity agents in Shionogi research pipeline

U. of Oklahoma researchers identify novel proapoptotic antitumor compounds

Rigel completes phase I/II study of R-112 for allergic rhinitis

New M3-selective muscarinic antagonists and their use described by Spanish scientists

Helsinn acquires Gelclair rights from Sinclair

Further positive results reported from phase Ib trial of Cancer Vac immunotherapy

Glucokinase activators: a novel class of antidiabetic agents

Antitumor activity of the novel coxib CS-706 (R-109339) in mice

SkyePharma licenses European Depocyte rights to Mundipharma

L-Lysine protease inhibitor with a unique resistance profile

MediciNova studying potential of SOCC-specific inhibitors for cancer

Nonpeptide T-20-like HIV entry inhibitors identified by New York Blood Center

Austrianova's cell therapy receives European orphan drug status

Tipranavir/ritonavir combination therapy in HIV infection

Recombinant human GH reported to induce changes in the lipid metabolism of HIV-infected patients

Nihon Shinyaku discontinues development of NS-7

NPS and Forest settle pending arbitration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...